Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1-2/2009

01.06.2009

Kinesin motor proteins as targets for cancer therapy

verfasst von: Dennis Huszar, Maria-Elena Theoclitou, Jeffrey Skolnik, Ronald Herbst

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1-2/2009

Einloggen, um Zugang zu erhalten

Abstract

The process of mitosis is a validated point of intervention in cancer therapy and a variety of anti-mitotic drugs are successfully being used in the clinic. To date, all approved antimitotics target the spindle microtubules, thus interfering with spindle dynamics, leading to mitotic arrest and apoptosis. While effective, these drugs are also associated with a variety of side effects, including neurotoxicity. In recent years, mitotic kinesins have attracted significant attention in the search for novel, alternative mitotic drug targets. Due to their specific function in mitosis, targeting these proteins creates an opportunity for the development of more selective antimitotics with an improved side effect profile. In addition, kinesin inhibitors may overcome resistance to microtubule targeting drugs. Drug discovery efforts in this area have initially focused on the plus-end directed kinesin spindle protein (KSP) and a variety of compounds are currently undergoing clinical testing.
Literatur
1.
Compton, D. A. (2000). Spindle assembly in animal cells. Annual Review of Biochemistry, 69, 95–114.PubMedCrossRef
2.
Cheesman, I. M., & Desai, A. (2008). Molecular architecture of the kinetochore-microtubule interphase. Nature Reviews Molecular and Cellular Biology, 9, 33–46.CrossRef
3.
Jordan, M. A., & Wilson, L. (2004). Microtubules as target for anticancer drugs. Nature Reviews Cancer, 4, 253–265.PubMedCrossRef
4.
Wood, K. W., Cornwell, W. D., & Jackson, J. R. (2001). Past and future of the mitotic spindle as an oncology target. Current Opinion in Pharmacology, 1, 370–377.PubMedCrossRef
5.
Musacchio, A., & Hardwick, K. G. (2002). The spindle checkpoint: Structural insights into dynamic signalling. Nature Reviews Molecular and Cellular Biology, 3, 731–741.CrossRef
6.
Miki, H., Okada, Y., & Hirokawa, N. (2005). Analysis of the kinesin superfamily: Insights into structure and function. Trends in Cell Biology, 15, 467–476.PubMedCrossRef
7.
Mountain, V., & Compton, D. A. (2000). Dissecting the role of molecular motors in the mitotic spindle. Anatomical Record (New Anat), 261, 14–24.CrossRef
8.
Hirokawa, N., & Takemura, R. (2004). Kinesin superfamily proteins and their various functions and dynamics. Experimental Cell Research, 301, 50–59.PubMedCrossRef
9.
Heck, M. M. S. (1999). Dr Dolittle and the making of the mitotic spindle. BioEssays, 21, 985–990.PubMedCrossRef
10.
Zhu, C., Zhao, J., Bibikova, M., Leverson, J. D., Bossy-Wetzel, E., Fan, J-B., et al. (2005). Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Molecular Biology of the Cell, 16, 3187–3199.PubMedCrossRef
11.
Mayer, T. U., Kapoor, T. M., Haggarty, S. J., King, R. W., Schreiber, S. L., & Mitchison, T. J. (1999). Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science, 286, 971–974.PubMedCrossRef
12.
LeGuellec, R., Paris, J., Couturier, A., Roghi, C., & Philippe, M. (1991). Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein. Molecular and Cellular Biology, 11, 3395–3398.
13.
Sawin, K. E., LeGuellec, K., Philippe, M., & Mitchison, T. J. (1992). Mitotic spindle organization by a plus-end-directed microtubule motor. Nature, 359, 540–543.PubMedCrossRef
14.
Valentine, M. T., Fordyce, P. M., & Block, S. M. (2006). Eg5 steps it up! Cell Division, 1, 31.PubMedCrossRef
15.
Kapitein, L. C., Peterman, E. J. G., Kwok, B. H., Kim, J. H., Kapoor, T. M., & Schmidt, C. F. (2005). The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature, 435, 114–118.PubMedCrossRef
16.
Heck, M. M. S., Pereira, A., Pesavento, P., Yannoni, Y., Spradling, A. C., & Goldstein, L. S. B. (1993). The kinesin-like protein KLP61F is essential for mitosis in Drosophila. Journal of Cell Biology, 123, 665–679.PubMedCrossRef
17.
Blangy, A., Lane, H. A., d’Herin, P., Harper, M., Kress, M., & Nigg, E. A. (1995). Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell, 83, 1159–1169.PubMedCrossRef
18.
Castillo, A., Morse, H. C., Godfrey, V. L., Naeem, R., & Justice, M. J. (2007). Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Research, 67, 10138–10147.PubMedCrossRef
19.
Castillo, A., & Justice, M. J. (2007). The kinesin related motor protein, Eg5, is essential for maintenance of pre-implantation embryogenesis. Biochemical and Biophysical Research Communications, 357, 694–699.PubMedCrossRef
20.
Chauviere, M., Kress, C., & Kress, M. (2008). Disruption of the mitotic kinesin Eg5 gene (Knsl1) results in early embryonic lethality. Biochemical and Biophysical Research Communications, 372, 513–519.PubMedCrossRef
21.
Carter, B. Z., Mak, D. H., Shi, Y., Schoeber, W. D., Wang, R. Y., Konopleva, M., et al. (2006). Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: Overcoming imatinib resistance. Cell Cycle, 5, 2223–2229.PubMed
22.
Hegde, P. S., Cogswell, J., Carrick, K., Jackson, J., Wood, K. W., Eng, W. K., et al. (2003). Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proceedings of the American Society of Clinical Oncology, 22, abstract 535.
23.
Saijo, T., Ishii, G., Ochiai, A., Yoh, K., Goto, K., Nagai, K., et al. (2006). Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimititic agents combined with platinum chemotherapy. Lung Cancer, 54, 217–225.PubMedCrossRef
24.
DeBonis, S., Skoufias, D. A., Lebeau, L., Lopez, R., Robin, G., Margolis, R. L., et al. (2004). In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Molecular Cancer Therapeutics, 3, 1079–1090.PubMed
25.
Sakowicz, R., Finer, J. T., Beraud, C., Crompton, A., Lewis, E., Fritsch, A., et al. (2004). Antitumor activity of a kinesin inhibitor. Cancer Research, 64, 3276–3280.PubMedCrossRef
26.
Marcus, A. I., Peters, U., Thomas, S. L., Garrett, S., Zelnak, A., Kapoor, T. M., et al. (2005). Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. Journal of Biological Chemistry, 280, 11569–11577.PubMedCrossRef
27.
Chin, G. M., & Herbst, R. (2006). Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Molecular Cancer Therapeutics, 5, 2580–2591.PubMedCrossRef
28.
Lemieux, C., DeWolf, W., Voegtli, W., DeLisle, R. K., Laird, E., Wallace, E., et al. (2007). ARRY-520: A novel, highly selective KSP inhibitor with potent anti-proliferative activity. AACR Annual Meeting.
29.
Woessner, R., Corrette, C., Allen, S., Hans, J., Zhao, Q., Aicher, T., et al. (2007). ARRY-520: A KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. AACR Annual Meeting.
30.
Weaver, B. A. A., & Cleveland, D. W. (2005). Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell, 8, 7–12.PubMedCrossRef
31.
Tao, W., South, V. J., Zhang, Y., Davide, J. P., Farrell, L., Kohl, N. E., et al. (2005). Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell, 8, 49–59.PubMedCrossRef
32.
Tao, W., South, V. J., Diehl, R. E., Davide, J. P., Sepp-Lorenzino, L., Fraley, M. E., et al. (2007). An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Molecular and Cellular Biology, 27, 689–698.PubMedCrossRef
33.
Vijapurkar, U., Wang, W., & Herbst, R. (2007). Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Research, 67, 237–245.PubMedCrossRef
34.
Shi, J., Orth, J. D., & Mitchison, T. (2008). Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Research, 68, 3269–3276.PubMedCrossRef
35.
Gascoigne, K. E., & Taylor, S. S. (2008). Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell, 14, 111–122.PubMedCrossRef
36.
Kappe, C. O., Shishkin, O. V., Uray, G., & Verdino, P. (2000). X-Ray structure, conformational analysis, enantioseparation, and determination of absolute configuration of the mitotic kinesin Eg5 inhibitor monastrol. Tetrahedron, 56, 1859–1862.CrossRef
37.
Yan, Y., Sardana, V., Xu, B., Homnick, C., Halczenko, W., Buser, C. A., et al. (2004). Inhibition of a mitotic motor protein: Where, how and conformational changes. Journal of Molecular Biology, 335, 547–554.PubMedCrossRef
38.
Bristol Myers Squibb (2002). WO2002079169.
39.
Bristol Myers Squibb (2002). WO2002079149.
40.
Leipzig University/Max-Planck Institute (2006). WO2006048308.
41.
Gartner, M., Sunder-Plassmann, N., Seiler, J., Utz, M., Vernos, I., Surrey, T., et al. (2005). Development and biological evaluation of potent and specific inhibitors of mitotic kinesin Eg5. ChemBioChem, 6, 1173–1177.PubMedCrossRef
42.
Sarli, V., Huemmer, S., Sunder-Plassmann, N., Mayer, T. U., & Giannis, A. (2005). Synthesis and biological evaluation of novel Eg5 inhibitors. ChemBioChem, 6, 2005–2013.PubMedCrossRef
43.
44.
Sorbera, L. A., Bolos, J., Serradell, N., & Bayes, M. (2006). Ispinesib mesilate. Drugs Future, 31, 778–787.CrossRef
45.
46.
47.
Bergnes, G., Ha, E., Feng, B., Smith, W. W., Yao, B., Tochimoto, T., et al. (2002). Mitotic kinesin-targeted antitumor agents: Discovery, lead optimization and anti-tumor activity of a series of novel quinazolinones as inhibitors of kinesin spindle protein (KSP). Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, MEDI-249.
48.
Cytokinetics/GSK (2003). WO2003103575.
49.
50.
51.
52.
53.
54.
Cytokinetics/GSK (2004). WO2004024086.
55.
Cytokinetics/GSK (2004). WO200406741.
56.
57.
Cytokinetics/GSK (2005). WO2005042697.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
Cytokinetics/GSK (2003). WO2003088903.
69.
70.
71.
72.
73.
Cytokinetics/GSK (2004). WO2004055008.
74.
75.
76.
77.
Cytokinetics/GSK (2003). WO2003094839.
78.
79.
Cytokinetics/GSK (2004). WO2004032840.
80.
81.
82.
83.
84.
85.
86.
87.
88.
Cox, C. D., Breslin, M. J., Mariano, B. J., Coleman, P. J., Buser, C. A., Walsh, E. S., et al. (2005). Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters, 15, 2041–2045.CrossRef
89.
Fraley, M. E., Garbaccio, R. M., Arrington, K. L., Hoffman, W. F., Tasber, E. S., Coleman, P. J., et al. (2006). Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters, 16, 1775–1779.CrossRef
90.
Garbaccio, R. M., Fraley, M. E., Tasber, E. S., Olson, C. M., Hoffman, W. F., Arrington, K. L., et al. (2006). Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorganic & Medicinal Chemistry Letters, 16, 1780–1783.CrossRef
91.
Cox, C. D., Torrent, M., Breslin, M. J., Mariano, B. J., Whitman, D. B., Coleman, P. J., et al. (2006). Kinesin spindle protein (KSP) inhibitors. Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters, 16, 3175–3179.CrossRef
92.
Cox, C. D., Breslin, M. J., Whitman, D. B., Coleman, P. J., Garbaccio, R. M., Fraley, M. E., et al. (2007). Kinesin spindle protein (KSP) inhibitors. Discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β -fluorination to overcome cellular efflux by P-glycoprotein. Bioorganic & Medicinal Chemistry Letters, 17, 2697–2702.CrossRef
93.
Coleman, P. J., Schreier, J. D., Cox, C. D., Fraley, M. E., Garbaccio, R. M., Buser, C. A., et al. (2007). Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters, 17, 5390–5395.CrossRef
94.
Garbaccio, R. M., Tasber, E. S., Neilson, L. A., Coleman, P. J., Fraley, M. E., Olson, C., et al. (2007). Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters, 17, 5671–5676.CrossRef
95.
Roecker, A. J., Coleman, P. J., Mercer, S. P., Schreier, J. D., Buser, C. A., Walsh, E. S., et al. (2007). Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters, 17, 5677–5682.CrossRef
96.
Cox, C. D., Coleman, P. J., Breslin, M. J., Whitman, D. B., Garbaccio, R. M., Fraley, M. E., et al. (2008). Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer. Journal of Medicinal Chemistry, 51, 4239–4252.PubMedCrossRef
97.
Kyowa Hakko/Fuji Film (2005). WO2005035512.
98.
Kyowa Hakko/Fuji Film (2005). JP2005232016.
99.
Kyowa Hakko/Fuji Film (2006). WO2006101102.
100.
101.
102.
Array Biopharma (2006). WO2006044825.
103.
Array Biopharma (2008). WO2008042928.
104.
105.
106.
107.
108.
109.
Sunder-Plassmann, N., Sarli, V., Gartner, M., Utz, M., Seiler, J., Huemmer, S., et al. (2005). Synthesis and biological evaluation of new tetrahydro-β -carbolines as inhibitors of the mitotic kinesin Eg5. Bioorganic & Medicinal Chemistry, 13, 6094–6111.CrossRef
110.
Nakazawa, J., Yajima, J., Usui, T., Ueki, M., Takatsuki, A., Imoto, M., et al. (2003). A novel action of terpendole E on the motor activity of mitotic kinesin Eg5. Chemistry & Biology, 10, 131–137.CrossRef
111.
112.
Okumura, H., Nakazawa, J., Tsuganezawa, K., Usui, T., Osada, H., Matsumoto, T., et al. (2006). Phenothiazine and carbazole-related compounds inhibit mitotic kinesin Eg5 and trigger apoptosis in transformed culture cells. Toxicology Letters, 166, 44–52.PubMedCrossRef
113.
114.
115.
116.
117.
118.
119.
120.
Brier, S., Lemaire, D., DeBonis, S., Forest, E., & Kozielski, F. (2006). Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. Journal of Molecular Biology, 360, 360–376.PubMedCrossRef
121.
Maliga, Z., & Mitchison, T. J. (2006). Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Chemical & Biology, 6, 2.CrossRef
122.
Rickert, K. W., Schaber, M., Torrent, M., Neilson, L. A., Tasber, E. S., Garbaccio, R., et al. (2008). Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Archives of Biochemistry and Biophysics, 469, 220–231.PubMedCrossRef
123.
Parrish, C. A., Adams, N. D., Auger, K. R., Burgess, J. L., Carson, J. D., Chaudhari, A. M., et al. (2007). Novel ATP-competitive kinesin spindle protein inhibitors. Journal of Medicinal Chemistry, 50, 4939–4952.PubMedCrossRef
124.
Luo, L., Parrish, C. A., Nevins, N., McNulty, D. E., Chaudhari, A. M., Carson, J. D., et al. (2007). ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nature Chemical Biology, 3, 722–726.PubMedCrossRef
125.
Jones, S. F., Plummer, E. R., Burris, H. A., Razak, A. R., Meluch, A. A., Bowen, C. J., et al. (2006). Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology, 24, 2027.
126.
Rodon, J., Till, E., Patnaik, A., Takimoto, C., Beeram, M., Williams, D., et al. (2006). Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors. European Journal of Cancer, Supplement, 4, 193.CrossRef
127.
Blagden, S. P., Molife, L. R., Seebaran, A., Payne, M., Reid, A. H. M., Protheroe, A. S., et al. (2008). A phase I trial of ispinesib, a kinesin spidle protein inhibitor, with docetaxel in patients with advanced solid tumors. British Journal of Cancer, 98, 894–899.PubMedCrossRef
128.
Souid, A., Dubowy, R. L., Greenwald Triplett, D., Ingle, A. M., Sun, J., Blaney, S. M., et al. (2008). Pediatric phase I trial and pharmacokinetic (PK) study of ispinesib (SB715992): A children’s oncology group phase I consortium study. Proceedings of the American Society of Clinical Oncology, 26, 10014.
129.
Lee, R. T., Beekman, K. E., Hussain, M., Davis, N. B., Clark, J. I., Thomas, S. P., et al. (2008). A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer, 6, 21–24.PubMedCrossRef
130.
Miller, K., Ng, C., Ang, P., Brufsky, A. M., Lee, S. C., Dees, E. C., et al. (2005). Phase II, open label study of ispinesib in Patients with locally advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium, 1089.
131.
Shahin, M. S., Braly, P., Rose, P., Malpass, T., Bailey, H., Alvarez, R. D., et al. (2007). A phase II, open-label study of ispinesib (SB-715992) in patients with platimun/taxane refractory or resistant relapsed ovarian cancer. Proceedings of the American Society of Clinical Oncology, 25, 5562.
132.
Holen, K. D., Belani, C. P., Wilding, G., Ramalingam, S., Heideman, J. L., Ramanathan, R. K., et al. (2006). Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. Proceedings of the American Society of Clinical Oncology, 24, 2000.
133.
O’Connor, O. A., Goy, A., Orlowski, R., Hainsworth, J. D., Leonard, J. P., Afanasyev, B., et al. (2008). A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on day 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. Proceedings of the American Society of Clinical Oncology, 26, 8539.
134.
Stephenson, J. J., Lewis, N., Martin, J. C., Ho, A., Li, J., Wu, K., et al. (2008). Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies. Proceedings of the American Society of Clinical Oncology, 26, 2516.
135.
Heath, E. I., Alousi, A., Eder, J. P., Valdivieso, M., Vasist, L. S., Appleman, L., et al. (2006). A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. Proceedings of the American Society of Clinical Oncology, 24, 2026.
136.
Wood, K. W., Sakowicz, R., Goldstein, L. S. B., & Cleveland, D. W. (1997). CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell, 91, 357–366.PubMedCrossRef
137.
Kapoor, T. M., Lampson, M. A., Hergert, P., Cameron, L., Cimini, D., Salmon, E. D., et al. (2006). Chromosomes can congress to the metaphase plate before biorientation. Science, 311, 388–391.PubMedCrossRef
138.
Schaar, B. T., Chan, G. K., Maddox, P., Salmon, E. D., & Yen, T. J. (1997). CENP-E function at kinetochores is essential for chromosome alignment. Journal of Cell Biology, 139, 1373–1382.PubMedCrossRef
139.
Yao, X., Abrieu, A., Zheng, Y., Sullivan, K. F., & Cleveland, D. W. (2000). CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nature Cell Biology, 2, 484–491.PubMedCrossRef
140.
Mao, Y., Abrieu, A., & Cleveland, D. W. (2003). Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell, 114, 87–98.PubMedCrossRef
141.
Yinghui, M., Ariane, A., & Cleveland, D. W. (2003). Activating and Silencing the Mitotic Checkpoint through CENP-E-Dependent Activation/Inactivation of BubR1. Cell, 114, 87–98.CrossRef
142.
McEwen, B. F., Chan, G. K., Zubrowski, B., Savoian, M. S., Sauer, M. T., & Yen, T. J. (2001). CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Molecular Biology of the Cell, 12, 2776–2789.PubMed
143.
Putkey, F. R., Cramer, T., Morphew, M. K., Silk, A. D., Johnson, R. S., McIntosh, J. R., et al. (2002). Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev. Cell, 3, 351–365.
144.
Weaver, B. A., Bonday, Z. Q., Putkey, F. R., Kops, G. J., Silk, A. D., & Cleveland, D. W. (2003). Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. Journal of Cell Biology, 162, 551–563.PubMedCrossRef
145.
Weaver, B. A. A., Silk, A. D., Montagna, C., Pascal Verdier-Pinard, C. P., & Cleveland, D. W. (2007). Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell, 11, 25–36.PubMedCrossRef
146.
Chua, P. R., Desai, R., Schauer, S. P., Cornwell, W., Gilmartin, A., Sutton, D., et al. (2007). Differential response of tumor cell lines to inhibition of the mitotic checkpoint regulator and mitotic kinesin, CENP-E. AACR-NCI-EORTC-2007.
147.
Sutton, D., Gilmartin, A. G., Kusnierz, A. M., Sung, C-M., Luo, L., Carson, J. D., et al. (2007). A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro. AACR-NCI-EORTC_2007.
148.
Sutton, D., Diamond, M., Faucette, L., Giardiniere, M., Zhang, S. Y., Vidal, J., et al. (2007). GSK-923295, a potent and selective CENP-E inhibitor, has broad spectrum activity against human tumor xenografts in nude mice. AACR 2007.
149.
Schafer-Hales, K., Iaconelli, J., Snyder, J. P., Prussia, A., Nettles, J. H., El-Naggar, A., et al. (2007). Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Molecular Cancer Therapeutics, 6, 1317–1328.PubMedCrossRef
150.
Ashar, H. R., James, L., Gray, K., Carr, D., Black, S., Armstrong, L., et al. (2000). Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. Journal of Biological Chemistry, 275, 30451–30457.PubMedCrossRef
151.
Corson, T. W., Huang, A., Tsao, M. S., & Gallie, B. L. (2005). KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene, 24, 4741–4753.PubMedCrossRef
152.
Corson, T. W., & Gallie, B. L. (2006). KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. International Journal of Cancer, 119, 1088–1094.CrossRef
153.
Corson, T. W., Zhu, C. Q., Lau, S. K., Shepherd, F. A., Tsao, M. S., & Gallie, B. L. (2007). KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clinical Cancer Research, 13, 3229–3234.PubMedCrossRef
154.
Carleton, M., Mao, M., Biery, M., Warrener, P., Kim, S., Buser, C., et al. (2006). RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Molecular and Cellular Biology, 26, 3853–3863.PubMedCrossRef
155.
Gruneberg, U., Neef, R., Li, X., Chan, E. H., Chalamalasetty, R. B., Nigg, E. A., et al. (2006). KIF14 and citron kinase act together to promote efficient cytokinesis. Journal of Cell Biology, 172, 363–372.PubMedCrossRef
156.
Kwon, M., Godinho, S. A., Chandhok, N. S., Ganem, N. J., Azioune, A., Thery, M., et al. (2008). Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes & Development, 22, 2189–2203.CrossRef
157.
Mayr, I. M., Hummer, S., Bormann, J., Gruner, T., Adio, S., Woehlke, G., et al. (2007). The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression. Current Biology, 17, 488–498.PubMedCrossRef
158.
Stumpf, J., von Dassow, G., Wagenbach, M., Asbury, C., & Wordeman, L. (2008). The kinesin-8 motor Kif18A suppresses kinetochore movements to control mitotic chromosome alignment. Developments in Cell, 14, 252–262.CrossRef
Metadaten
Titel
Kinesin motor proteins as targets for cancer therapy
verfasst von
Dennis Huszar
Maria-Elena Theoclitou
Jeffrey Skolnik
Ronald Herbst
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1-2/2009
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-009-9185-8

Weitere Artikel der Ausgabe 1-2/2009

Cancer and Metastasis Reviews 1-2/2009 Zur Ausgabe

NON-THEMATIC REVIEW

Osteosarcoma treatment: state of the art

OriginalPaper

EMT, the cytoskeleton, and cancer cell invasion

OriginalPaper

Targeting group II PAKs in cancer and metastasis

OriginalPaper

Tumor stroma derived biomarkers in cancer

OriginalPaper

Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion

Acknowledgments

Biographies

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise